Recordati S.p.A.
REC.MINext catalyst
osilodrostat
Cushing's Syndrome
Get an email about REC.MI's next catalysts
Track Recordati S.p.A. (REC.MI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 2 readout).See the timeline
3 upcoming, 1 past
osilodrostat Phase 2 Est. Readout
Estimated primary completion for osilodrostat trial (NCT07104812) in Mild Autonomous Cortisol Secretion. Topline data typically follows completion by weeks to months.
SourcePasireotide Phase 2 Est. Readout
Estimated primary completion for Pasireotide trial (NCT06295952) in Prolactin-Producing Pituitary Tumor. Topline data typically follows completion by weeks to months.
SourceLCI699 Phase 2 Est. Readout
Estimated primary completion for LCI699 trial (NCT03708900) in Cushing Syndrome. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Methadone
Pain Related to Cancer
Mercaptamine
Cystinosis
Silodosin
Benign Prostatic Hyperplasia
Lercanidipine
Essential Hypertension
Rec 0/0438
Neurogenic Detrusor Overactivity
Pasireotide Diaspartate
Post-Bariatric Hypoglycemia
LCI699
Cushing Syndrome
Pasireotide Long Acting Release (LAR)
Neuroendocrine Tumors
Dinutuximab Beta, Zoledronic acid, Interleukin-2
Leiomyosarcoma
Pasireotide
Prolactin-Producing Pituitary Tumor
Hemin
Gastroparesis
Siltuximab
Multiple Myeloma
Erenumab-Aooe
Schwannomatosis
Lercanidipine + Enalapril
Essential Hypertension
Udonitrectag
Neurotrophic Keratitis
osilodrostat
Cushing's Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Methadone | Phase 3 | Pain Related to Cancer | - | - |
Mercaptamine | Phase 3 | Cystinosis | - | - |
Silodosin | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Lercanidipine | Phase 2 | Essential Hypertension | - | - |
Rec 0/0438 | Phase 2 | Neurogenic Detrusor Overactivity | - | - |
Pasireotide Diaspartate | Phase 2 | Post-Bariatric Hypoglycemia | - | - |
LCI699 | Phase 2 | Cushing Syndrome | - | - |
Pasireotide Long Acting Release (LAR) | Phase 2 | Neuroendocrine Tumors | - | - |
Dinutuximab Beta, Zoledronic acid, Interleukin-2 | Phase 2 | Leiomyosarcoma | - | - |
Pasireotide | Phase 2 | Prolactin-Producing Pituitary Tumor | - | - |
Hemin | Phase 2 | Gastroparesis | - | - |
Siltuximab | Phase 2 | Multiple Myeloma | - | - |
Erenumab-Aooe | Phase 2 | Schwannomatosis | - | - |
Lercanidipine + Enalapril | Phase 2 | Essential Hypertension | - | - |
Udonitrectag | Phase 2 | Neurotrophic Keratitis | - | - |
osilodrostat | Phase 2 | Cushing's Syndrome | - | - |
Frequently asked questions
What is in Recordati S.p.A.'s drug pipeline?→
CatalystAlert tracks 16 drug candidates in Recordati S.p.A.'s (REC.MI) pipeline across Phase 3, Phase 2. Its lead program is Mercaptamine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Recordati S.p.A.'s next FDA catalyst?→
Recordati S.p.A.'s (REC.MI) next tracked catalyst is a Phase 2 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REC.MI biotech catalysts?→
Add REC.MI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Recordati S.p.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
